Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1233 ARTÍCULOS , VIENDO DEL 1036 AL 1050

Multimedia Aided Consent for Alzheimer's Disease Research

Palmer BW, Harmell AL, Dunn LB, Kim SY, Pinto LL, Golshan S, Jeste DV.

Clin Gerontol. 2018 Jan-Feb;41(1):20-32. doi: 10.1080/07317115.2017.1373177. Epub 2017 Nov 28.

Qualitative analysis of the capacity to consent to treatment in patients with a chronic neurodegenerative disease: Alzheimer's disease / Analisi qualitativa sulla capacità a prestare consenso al trattamento in pazienti con malattie cronico degenerative neuropsicoorganiche: Demenza di Alzheimer

Carabellese F, Felthous AR, La Tegola D, Piazzolla G, Distaso S, Logroscino G, Leo A, Ventriglio A, Catanesi R.

Int J Soc Psychiatry. 2018 Feb;64(1):26-36. doi: 10.1177/0020764017739642. Epub 2017 Nov 28.

Nutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer's disease

Sadhukhan P, Saha S, Dutta S, Mahalanobish S, Sil PC.

Pharmacol Res. 2018 Mar;129:100-114. doi: 10.1016/j.phrs.2017.11.028. Epub 2017 Nov 26.

Extracellular Vesicle Biology in Alzheimer's Disease and Related Tauopathy

DeLeo AM, Ikezu T.

J Neuroimmune Pharmacol. 2018 Sep;13(3):292-308. doi: 10.1007/s11481-017-9768-z. Epub 2017 Nov 28.

Optimal mesenchymal stem cell delivery routes to enhance neurogenesis for the treatment of Alzheimer's disease: optimal MSCs delivery routes for the treatment of AD

Park SE, Lee NK, Na DL, Chang JW.

Histol Histopathol. 2018 Jun;33(6):533-541. doi: 10.14670/HH-11-950. Epub 2017 Nov 29.

Microglia in Alzheimer's disease

Hansen DV, Hanson JE, Sheng M.

J Cell Biol. 2018 Feb 5;217(2):459-472. doi: 10.1083/jcb.201709069. Epub 2017 Dec 1.

Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease

Camargo LC, Campos GAA, Galante P, Biolchi AM, Gonçalves JC, Lopes KS, Mortari MR.

Neuropeptides. 2018 Feb;67:79-86. doi: 10.1016/j.npep.2017.11.010. Epub 2017 Nov 28.

Almond, hazelnut and walnut, three nuts for neuroprotection in Alzheimer's disease: A neuropharmacological review of their bioactive constituents

Gorji N, Moeini R, Memariani Z.

Pharmacol Res. 2018 Mar;129:115-127. doi: 10.1016/j.phrs.2017.12.003. Epub 2017 Dec 5.

ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target

Davis W Jr, Tew KD.

Biochem Pharmacol. 2018 May;151:188-200. doi: 10.1016/j.bcp.2017.11.018. Epub 2017 Dec 6.

Obstructive sleep apnoea and Alzheimer's disease: In search of shared pathomechanisms

Polsek D, Gildeh N, Cash D, Winsky-Sommerer R, Williams SCR, Turkheimer F, Leschziner GD, Morrell MJ, Rosenzweig I.

Neurosci Biobehav Rev. 2018 Mar;86:142-149. doi: 10.1016/j.neubiorev.2017.12.004. Epub 2017 Dec 7.

Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease

Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Joni Shah N, Langen KJ, Kutzsche J, Willbold D, Willuweit A.

Eur J Pharm Sci. 2018 Mar 1;114:93-102. doi: 10.1016/j.ejps.2017.12.005. Epub 2017 Dec 7.

Reactive astrocytes in Alzheimer's disease: A double-edged sword

Chun H, Lee CJ.

Neurosci Res. 2018 Jan;126:44-52. doi: 10.1016/j.neures.2017.11.012. Epub 2017 Dec 7.

Amylin in Alzheimer's disease: Pathological peptide or potential treatment?

Mietlicki-Baase EG.

Neuropharmacology. 2018 Jul 1;136(Pt B):287-297. doi: 10.1016/j.neuropharm.2017.12.016. Epub 2017 Dec 9.

Alzheimer's disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence

Mancuso C, Santangelo R.

Pharmacol Res. 2018 Mar;129:329-336. doi: 10.1016/j.phrs.2017.12.009. Epub 2017 Dec 9.

Suvorexant for the treatment of insomnia in patients with Alzheimer's disease

Hamuro A, Honda M, Wakaura Y.

Aust N Z J Psychiatry. 2018 Feb;52(2):207-208. doi: 10.1177/0004867417747402. Epub 2017 Dec 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias